Pursuing an answer to a compelling question

Our technology was developed to address an intriguing challenge: How to deliver a time-release medication into the epidural space. Our novel Clonidine Micropellet is designed to provide an answer to that question. Since our founding, Sollis has received support from a variety of non-profit and for-profit entities that recognize the unique potential of our platform.

Focused on improving peoples’ lives

Sollis is committed to developing therapies that positively impact millions of lives. Our Clonidine Micropellet investigational therapy offers the potential to positively impact patients across a range of indications. Our goal is to provide new treatments designed to improve patient safety and quality of life, helping patients resume normal life and return to work sooner. This may also help reduce costs, with sciatica estimated to cost $21 billion in absenteeism in the U.S.1

The Sollis Clonidine Micropellet therapy is an investigational treatment for sciatica and has not been approved for use by the FDA.

  1. Source: National Health Interview Survey (NHIS)_Adult sample, 2012. https://www.cdc.gov/nchs/nhis/nhis_2012_data_release.htm